Okyo Pharma Ltd - Guernsey-based ophthalmology-focused bio-pharmaceutical company, currently developing OK-101 to treat dry eye disease - New shares will be listed on Nasdaq in New York from Monday, following a share consolidation and the termination of its American depository share programme. Okyo has been listed on Nasdaq via the ADS programme since May last year. Okyo shares will be de-listed from the London Stock Exchange on Monday. De-listing had been planned for a week ago but was postponed. Each new Okyo share will represent 65 old shares and be equal to one old ADS.
Current stock price in London: 1.70 pence
12-month change: down 62%
By Emma Curzon, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.